Last reviewed · How we verify

NCT05626205: PARO

Psycho-social Intervention With Paro Robotic Seal Focused on Patients With Dementia

Status unknown NA Last updated 5 March 2024
What this trial tests

NA trial testing PARO robot in Alzheimer Disease in 20 participants. Status unknown.

Timeline
5 November 2022
Primary endpoint
30 March 2024
30 March 2024

Quick facts

Lead sponsorIstituto Nazionale di Ricovero e Cura per Anziani
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Enrollment20
Start date5 November 2022
Primary completion30 March 2024
Estimated completion30 March 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Istituto Nazionale di Ricovero e Cura per Anziani — full company profile →

Who can join

65 and older, any sex, with Alzheimer Disease or Older Adults. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overall objective of the study is to evaluate the improvement in patient-perceived quality of life following the use of the Paro robot integrated with traditional intervention in the elderly with dementia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Social robotics to support older people with dementia: a study protocol with Paro seal robot in an Italian Alzheimer's day center.
    Bevilacqua R, Maranesi E, Felici E, Margaritini A, et al · · 2023 · cited 5× · PMID 37415712 · DOI 10.3389/fpubh.2023.1141460

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

Other Istituto Nazionale di Ricovero e Cura per Anziani trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05626205.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing